|
Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12e
| Section II. Neuropharmacology > |
Chapter 15. Drug Therapy of Depression and Anxiety Disorders
Sections: Drug Therapy of Depression and Anxiety Disorders: Introduction, Characterization of Depressive and Anxiety Disorder, Antidepressant Drugs, Monoamine Oxidase Inhibitors, Tricyclic Antidepressant and Selective Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Serotonin Receptor Antagonists, Bupropion, Atypical Antipsychotics, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Anxiolytic Drugs, Clinical Summary, Bibliography.
Topics Discussed: anti-anxiety agents; antidepressive agents; anxiety; anxiety disorder; anxiety disorders i: generalized anxiety, panic, and social anxiety disorders; depressive disorders; pharmacotherapy of psychiatric disorders.
Excerpt:"Depression and anxiety disorders are the most common mental illnesses, each affecting in excess of 10-15% of the population at some time in their lives. Both anxiety and depressive disorders are amenable to pharmacological treatments that have been developed since the 1950s. With the discovery of more selective and safer drugs, the use of antidepressants and anxiolytics has moved from the domain of psychiatry to other medical specialties, including primary care. The relative safety of the majority of commonly used antidepressants and anxiolytics notwithstanding, their optimal use requires a clear understanding of their mechanisms of action, pharmacokinetics, potential drug interactions, and the differential diagnosis of psychiatric illnesses...."
The content above is only an excerpt.
For full access, log into an existing user account below,
purchase an annual subscription, or
purchase a short-term subscription to the complete website.
|
|
|
|
Or
|
|
|
|